Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
NCT06690281 · National Cancer Institute (NCI) · PHASE2 · withdrawn · last registry update 2025-09-11 · Pancreatic cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI left NIH.” | Open Targets' class: study staff moved | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL2RA in pancreatic cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-09-01Also stopped (terminated): Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, TCR-T therapy (NCT05438667)
- 2026-05-19Results posted on the registry: National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT03745326)
- 2026-05-19Also stopped (terminated): National Cancer Institute (NCI), Cyclophosphamide + Fludarabine (NCT03745326)
- 2025-12-24Also stopped (withdrawn): City of Hope Medical Center, Aldesleukin + Cyclophosphamide (NCT06626256)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision